Can-Fite BioPharma (CANF) Times Interest Earned (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly Times Interest Earned came in at -$0.07 in Q4 2023, down 54.29% YoY from -$0.15 in Q4 2022, and up 96.25% on a QoQ basis from -$1.83 in Q2 2023.
Can-Fite BioPharma (CANF) Times Interest Earned (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Times Interest Earned data on file, last reported at -$0.07 in Q4 2023.
- Quarterly Times Interest Earned fell 54.29% year-over-year to -$0.07 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$0.31 (up 0.56% YoY) and the FY2025 annual result came in at -$0.29, down 0.73% from the prior year.
- Times Interest Earned advanced to -$0.07 in Q4 2023, from -$1.83 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $53.08 in Q2 2019 to a low of -$8.59 in Q4 2019.
- A 5-year average of $6.32 and a median of -$0.07 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2019 — Times Interest Earned surged 469.92% — and 2021, when it tumbled 4052.2%.
- Tracing CANF's Times Interest Earned over 5 years: stood at -$8.59 in 2019, then jumped by 98.85% to -$0.1 in 2020, then plunged by 4052.2% to -$4.11 in 2021, then soared by 98.92% to -$0.04 in 2022, then tumbled by 54.29% to -$0.07 in 2023.
- The last three Times Interest Earned figures came in at -$0.07 (Q4 2023), -$1.83 (Q2 2023), and -$0.04 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.07 |
| Jun 30, 2023 | -1.83 |
| Dec 31, 2022 | -0.04 |
| Dec 31, 2021 | -4.11 |
| Dec 31, 2020 | -0.10 |
| Dec 31, 2019 | -8.59 |
| Sep 30, 2019 | 5.38 |
| Jun 30, 2019 | 53.08 |
| Mar 31, 2019 | 13.16 |
| Dec 31, 2018 | -5.61 |
| Sep 30, 2018 | -1.45 |
| Jun 30, 2018 | 41.48 |
| Mar 31, 2018 | 11.42 |
| Dec 31, 2017 | 45.65 |
| Sep 30, 2017 | -72.94 |
| Jun 30, 2017 | 16.63 |
| Mar 31, 2017 | 61.74 |
| Dec 31, 2016 | 46.00 |
| Sep 30, 2016 | 9.98 |
| Jun 30, 2016 | -9.12 |